Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib

References

• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899.
   PubMed Web of Science ®Google Scholar
• Wassermann J, Bernier MO, Spano JP, et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist. 2016;21(1):50–58.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
   PubMed Web of Science ®Google Scholar
• Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(8):1126–1138.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–2756.
   PubMed Web of Science ®Google Scholar
• Lenvima EMA SmPC. cited 2022 Mar 10) https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_fr.pdf
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (cited 2020 Mar 10).https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf
   Google Scholar
• Haddad RI, Schlumberger M, Wirth LJ, et al., Incidence and timing of common adverse events in lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017. 56(1): 121–128.
   PubMed Web of Science ®Google Scholar
• Brose MS, Panaseykin Y, Konda B, et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrin Metab. 2022;107(3):776–787.
   PubMed Web of Science ®Google Scholar
• Tahara M, Brose MS, Wirth LJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61–68.
   PubMed Web of Science ®Google Scholar
• Gianoukakis AG, Dutcus CE, Batty N, et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer. 2018;25(6):699–704.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019;46(1):57–64.
   PubMed Web of Science ®Google Scholar
• Resteghini C, Cavalieri S, Galbiati D, et al. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res Clin Endocrinol Metab. 2017;31(3):349–361.
   PubMed Web of Science ®Google Scholar
• Reed N, Glen H, Gerrard G, et al., Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer. Clin Oncol. 2020. 32(5): e145–e153.
   Web of Science ®Google Scholar
• Sueta D, Suyama K, Sueta A, et al. An oral multi-kinases inhibitor, -associated hypertension: potential role of vascular endothelial dysfunction. Atherosclerosis. 2017 May;260:116–120.
   PubMed Web of Science ®Google Scholar
• Lamore SD, Kohnken RA, Peters MF, et al. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol. 2020 Jan 21;33(1):125–136.
   PubMed Web of Science ®Google Scholar
• Ollero M, Sahali D. Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant. 2015 Sep;30(9):1449–1455.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Mancia G, et al. Harmonization of the American college of cardiology/american heart association and European society of cardiology/European society of hypertension blood pressure/hypertension guidelines. Eur Heart J. 2022 Sep 14;43(35):3302–3311.
   PubMed Web of Science ®Google Scholar
• LenvimaTM Highlights of prescribing information. (cited 2020 Mar 10).https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf
   Google Scholar
• Ancker OV, Wehland M, Bauer J, et al. The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors. Int J Mol Sci. 2017 Mar 14;18(3):625.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334–e347.
   PubMed Web of Science ®Google Scholar
• Porta-Sánchez A, Gilbert C, Spears D, et al., Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017. 6(12): ii:e007724.
   Web of Science ®Google Scholar
• Walraven M, Witteveen PO, Lolkema MP, et al. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011 May;14(2):135–141.
   PubMed Web of Science ®Google Scholar
• Staub Y, Nishiyama A, Suga Y, et al. Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Anticancer Res. 2019 Jul;39(7):3871–3878.
   PubMed Web of Science ®Google Scholar
• Valerio L, Giani C, Agate L, et al. Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J. 2021 Jul;10(5):399–407.
   PubMed Web of Science ®Google Scholar
• Robinson B, Schlumberger M, Wirth LJ, et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016 Nov;101(11):4103–4109.
   PubMed Web of Science ®Google Scholar
• Cavalieri S, Cosmai L, Genderini A, et al. Lenvatinib-induced renal failure: two first-time case reports and review of literature. Exp Opin Drug Metab Toxicol. 2018;14(4):379–385.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Escudier B, Lhomme C, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93(24):333–339.
   PubMed Web of Science ®Google Scholar
• Hyogo Y, Kiyota N, Otsuki N, et al. Thrombotic microangiopathy with severe proteinuria induced by lenvatinib for radioactive iodine-refractory papillary thyroid carcinoma. Case Rep Oncol. 2018;11(3):735–741.
   PubMed Web of Science ®Google Scholar
• Furuto Y, Hashimoto H, Namikawa A, et al. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol. 2018;19(1):273.
   PubMedGoogle Scholar
• Jhaveri KD, Flombaum CD, Kroog G, et al. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract. 2011;117(4):c312–9.
   PubMedGoogle Scholar
• Estrada CC, Maldonado A, Mallipattu SK, et al. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187–200.
   PubMed Web of Science ®Google Scholar
• Inkler LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–735.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes, CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):1–150.
   Web of Science ®Google Scholar
• Nervo A, Retta F, Ragni A, et al. Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: an update. Crit Rev Oncol Hematol. 2021 Dec;168:103533.
   PubMed Web of Science ®Google Scholar
• Gaillard V, Lhuillier A, Bigot C, et al. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study. Support Care Cancer. 2022 Aug;30(8):6583–6591.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Horinouchi A, Uozumi S, et al. Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. SAGE Open Med. 2020 Jun 12;8:2050312120930906.
   Web of Science ®Google Scholar
• Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017 Jul 11;318(2):197–198.
   PubMed Web of Science ®Google Scholar